OptiNose Inc (OPTN)
1.26
-0.03
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
OptiNose Total Liabilities (Quarterly): 182.92M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 182.92M |
December 31, 2023 | 194.34M |
September 30, 2023 | 179.02M |
June 30, 2023 | 175.73M |
March 31, 2023 | 188.71M |
December 31, 2022 | 200.85M |
September 30, 2022 | 178.69M |
June 30, 2022 | 183.62M |
March 31, 2022 | 178.67M |
December 31, 2021 | 187.84M |
September 30, 2021 | 183.39M |
June 30, 2021 | 176.59M |
March 31, 2021 | 174.61M |
December 31, 2020 | 182.02M |
September 30, 2020 | 153.34M |
Date | Value |
---|---|
June 30, 2020 | 140.44M |
March 31, 2020 | 139.04M |
December 31, 2019 | 111.07M |
September 30, 2019 | 104.86M |
June 30, 2019 | 98.10M |
March 31, 2019 | 100.64M |
December 31, 2018 | 98.38M |
September 30, 2018 | 94.89M |
June 30, 2018 | 95.62M |
March 31, 2018 | 94.45M |
December 31, 2017 | 86.64M |
September 30, 2017 | 68.57M |
June 30, 2017 | 6.225M |
December 31, 2016 | 45.39M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
98.10M
Minimum
Jun 2019
200.85M
Maximum
Dec 2022
165.69M
Average
178.68M
Median
Total Liabilities (Quarterly) Benchmarks
Madrigal Pharmaceuticals Inc | 231.52M |
Viking Therapeutics Inc | 33.63M |
Zevra Therapeutics Inc | 102.46M |
CytomX Therapeutics Inc | 216.37M |
Spero Therapeutics Inc | 71.45M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 83.71M |
Shareholders Equity (Quarterly) | -99.22M |
Debt to Equity Ratio | -1.317 |
Current Ratio | 2.480 |
Net Debt Paydown Yield | -0.25% |